Brokers Offer Predictions for EWTX Q2 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Edgewise Therapeutics in a report issued on Monday, June 30th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.41) for the quarter. HC Wainwright currently has a "Buy" rating and a $42.00 target price on the stock. The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.97) EPS and FY2029 earnings at $3.10 EPS.

A number of other equities analysts have also weighed in on the company. Guggenheim assumed coverage on Edgewise Therapeutics in a research report on Wednesday, April 30th. They issued a "buy" rating and a $41.00 price target for the company. Scotiabank cut shares of Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and decreased their target price for the stock from $50.00 to $14.00 in a report on Wednesday, April 2nd. Wedbush reissued an "outperform" rating and issued a $43.00 target price on shares of Edgewise Therapeutics in a research report on Monday, April 21st. Piper Sandler restated an "overweight" rating and issued a $51.00 price target on shares of Edgewise Therapeutics in a research report on Wednesday, April 2nd. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $48.00 price objective on shares of Edgewise Therapeutics in a research report on Thursday, June 5th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Edgewise Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.00.

Edgewise Therapeutics Price Performance

Shares of EWTX traded up $0.19 during trading hours on Wednesday, hitting $13.01. 506,561 shares of the company were exchanged, compared to its average volume of 1,189,467. The firm has a fifty day simple moving average of $14.74 and a 200-day simple moving average of $20.88. The company has a market capitalization of $1.37 billion, a PE ratio of -8.39 and a beta of 0.25. Edgewise Therapeutics has a one year low of $10.60 and a one year high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.02.

Insider Transactions at Edgewise Therapeutics

In other news, General Counsel John R. Moore sold 1,930 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total transaction of $31,748.50. Following the transaction, the general counsel directly owned 6,531 shares in the company, valued at $107,434.95. The trade was a 22.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alan J. Russell sold 1,551 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $16.45, for a total value of $25,513.95. Following the completion of the transaction, the insider owned 18,521 shares in the company, valued at $304,670.45. This trade represents a 7.73% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,258 shares of company stock worth $234,544. 23.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of hedge funds have recently added to or reduced their stakes in EWTX. Diadema Partners LP bought a new position in shares of Edgewise Therapeutics during the 4th quarter valued at $36,000. Jones Financial Companies Lllp bought a new position in Edgewise Therapeutics during the first quarter valued at about $47,000. GF Fund Management CO. LTD. acquired a new stake in shares of Edgewise Therapeutics in the fourth quarter worth about $53,000. Allostery Investments LP bought a new stake in shares of Edgewise Therapeutics during the 1st quarter worth about $66,000. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Edgewise Therapeutics by 55.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,194 shares of the company's stock valued at $70,000 after acquiring an additional 1,141 shares during the last quarter.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.